Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This trial is an exploratory randomised, parallel-group, double-blind, placebo- controlled,
national, single-centre trial.
The trial will be initiated before 2013 grass pollen season and subjects will be randomised
in September 2013 to receive active treatment (Grazax®) or placebo during 2 years. Placebo
group will be treated 2 years with placebo and a third year with active therapy (Grazax®) and
active group will continue the active treatment in the third year. In the last year, all
placebo patients will be changed to active group and active and placebo patients will be
informed about, but the trial will not be unblinded until the end of the third year and
patients won´t know what treatment they were assigned to during the first 2 years.